Scienture Holdings, Inc. SCNX 深 沪
等待开盘 03-26 09:30:00 美东时间
0.4598
0.000
-0.07%
华盛通- 最 高0.4702
- 今 开0.4643
- 成交量 24.42万股
- 最 低 0.4439
- 昨 收 0.4601
- 总市值 1868.20万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 0.372
- 委 比 -23.08%
- 总股本 4063.08万
- 历史最高 164.50
- 量 比 0.61
- 振 幅 5.72%
- 历史最低 -5.81
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US institutions and first responders.
03-11 19:46
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Maxim Group Initiates Coverage On Scienture Holdings with Buy Rating, Announces Price Target of $1.5
Maxim Group analyst Naz Rahman initiates coverage on Scienture Holdings (NASDAQ:SCNX) with a Buy rating and announces Price Target of $1.5.
02-25 01:39
SCIENTURE HOLDINGS Reaffirms Plan To Commercially Roll Out REZENOPY In Q2
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development,
02-03 21:21
Scienture Expands Access to ARBLI and Prepares for Launch of REZENOPY in 2026
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development,
02-03 21:20
EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment
New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.
01-14 20:51
Scienture Advances Commercial Launch Of FDA-Approved REZENOPY Following Exclusive U.S. Commercialization Agreement
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annuallyCOMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned
2025-12-22 21:07
Why Is Scienture Stock Gaining Today?
Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.
2025-12-10 22:53
Scienture Holdings Q3 EPS $(0.19) Up From $(1.34) YoY, Sales $590.050K Up From $64.861K YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.19) per share. This is a 85.82 percent increase over losses of $(1.34) per share from the same period last year. The company reported $590.050 thousand
2025-11-13 21:21
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
Scienture's Q3 revenue surged on Arbli sales, debt dropped, and cash rose to $8 million ahead of its planned Rezenopy launch in early 2026.
2025-11-13 20:50
